Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomi

Stock Information for Osiris Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Osiris Therapeutics Inc.

Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
Report: Exploring Fundamental Drivers Behind iPic Entertainment, Smith Micro Software, Northern Technologies International, Intevac, Helius Medical Technologies, and Osiris Therapeutics - New Horizons, Emerging Trends, and Upcoming Developments
Osiris Therapeutics, Inc Reports Third Quarter 2018 Results
Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada
Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage
Osiris Therapeutics, Inc. Announces GrafixPL PRIME(TM) Launches October 1, 2018
Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018
Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME(TM) in the Treatment of Chronic Venous Leg Ulcers

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.